Investment Thesis
Xilio demonstrates exceptional revenue growth (+590% YoY) and maintains a strong cash position ($137.5M) with zero debt, indicating successful early commercialization. However, severe operating losses (-$42M) with -95.9% operating margins and negative operating cash flow (-$5M quarterly) reveal unsustainable unit economics that must improve significantly to justify continued investment.
Strengths
- Extraordinary revenue growth of 589.9% YoY suggests successful product commercialization and market traction
- Strong cash position of $137.5M with zero debt provides 5-7 year runway to achieve profitability
- Favorable balance sheet with 2.58x current ratio and positive equity cushion of $35.3M
Risks
- Operating losses of $42M on $43.8M revenue represent -95.9% operating margin, indicating fundamental profitability challenges
- Negative operating cash flow of -$5M per quarter demonstrates cash burn despite revenue growth, unsustainable long-term
- Pharmaceutical sector risks including regulatory delays, clinical trial failures, market adoption uncertainty, and competitive threats
Key Metrics to Watch
- Path to operating profitability and gross margin expansion as revenue scales
- Operating cash flow trend and cash burn rate relative to revenue growth rate
- Cash runway depletion timeline and need for capital raise or profitability inflection
Financial Metrics
Revenue
43.8M
Net Income
-35.0M
EPS (Diluted)
$-4.19
Free Cash Flow
-5.5M
Total Assets
154.7M
Cash
137.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-95.9%
Net Margin
-80.1%
ROE
-99.3%
ROA
-22.6%
FCF Margin
-12.6%
Balance Sheet & Liquidity
Current Ratio
2.58x
Quick Ratio
2.58x
Debt/Equity
0.00x
Debt/Assets
77.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-19T14:12:23.309246 |
Data as of: 2025-12-31 |
Powered by Claude AI